Biotech luminary Sage Therapeutics is boosting the size of its planned IPO, upping its share offering and expected price range as investors look to its Wall Street debut as a bellwether for the industry.
St. Jude Medical is celebrating positive second-quarter sales fueled by tried-and-true products, but the devicemaker wants to capitalize on an untapped niche in the coming year by focusing on renal denervation.
A biochemist has designed a method for improving the treatment of hemophilia using a plant-based drug delivery system that combats resistance to standard clotting factors, which afflicts about one-fourth of those with the disease.
The blockbuster duo of GlaxoSmithKline and Theravance are pushing a new respiratory combo therapy into late-stage study, pooling the active ingredients from its last two approved COPD treatments to create a once-daily inhaler.
Patients with pancreatic cancer whose disease still persists after regular treatments may benefit from a new cancer drug nanoliposome formulation, according to a presentation at the European Society for Molecular Oncology's 16th World Congress on Gastrointestinal Cancer.
Researchers in Chicago have developed a method by which to deliver a breast cancer-preventing drug through the skin to avoid some of the nasty side effects associated with oral ingestion of the drug.
Immunocore has struck another cancer R&D pact with one of the world's top drugmakers, signing a deal with Eli Lilly that'll both bring in short-term revenue and help the biotech build value in its proprietary pipeline.
Merck KGaA, in the middle of a reformation plot in its biopharma division, has found a new head of drug R&D, moving on after its last research chief lasted just 6 months in the job.
With antibiotic resistance on the rise at a time when Big Pharma has largely left the risk-heavy field, the President's Council of Advisors on Science and Technology is proposing a number of recommendations to lure companies back into the arena and help speed up the development of new antibiotics.
480 Biomedical won $1 million in Phase II funding from the National Heart, Lung, and Blood Institute (NHLBI) to support development of its self-expanding scaffold for patients with pediatric artery stenosis (PAS).